Live Salesforce, Inc. Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow CANNAPHARMARX, INC.

Get SEC filing alerts via email and in your feed for CANNAPHARMARX, INC.

CPMD

CANNAPHARMARX, INC.

About CANNAPHARMARX, INC.

CannaPharmaRx, Inc. operates licensed cannabis cultivation and processing facilities in Canada, producing high-quality dried medical cannabis flower. The company focuses on indoor cultivation under strict regulatory standards, targeting medical and recreational cannabis markets primarily in Canada, with plans to serve European and Israeli markets. Its business model centers on compliant production, quality control, and distribution of cannabis products, leveraging licenses and certifications to meet evolving regulatory requirements.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from CANNAPHARMARX, INC.

1
1
CANNAPHARMARX, INC. CannaPharmaRx Reports 87% Revenue Increase but Faces Financial Challenges in Q1 2026

Via official filing (AI summary) | 14 days ago | 0 comments

2
1
CANNAPHARMARX, INC. CannaPharmaRx Reports $1.36 Million Revenue for Fiscal Year 2025 Amid Continued Losses

Via official filing (AI summary) | 2 months ago | 0 comments

3
1
CANNAPHARMARX, INC. CannaPharmaRx Reports Revenue Growth but Faces Significant Net Loss and Liquidity Challenges

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
CANNAPHARMARX, INC. CannaPharmaRx Reports Revenue Growth to $231,608 but Faces Significant Losses in Q2 2025

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
CANNAPHARMARX, INC. CannaPharmaRx Reports Revenue Growth to $335,319 but Faces Financial Challenges

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
CANNAPHARMARX, INC. CannaPharmaRx Reports First Revenue of $820K Amid $9.9M Net Loss in 2024

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
CANNAPHARMARX, INC. CannaPharmaRX Reports Revenue Growth, Improved Operating Expenses, and Cash Position, Despite Net Loss and Liquidity Concerns

Via official filing (AI summary) | over 1 year ago | 0 comments